STOCK TITAN

MapLight Therapeutics (MPLT) S-3 Filings

MPLT NASDAQ

Here are the S-3 shelf registrations from MapLight Therapeutics, Inc. (MPLT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.

Rhea-AI Summary

MapLight Therapeutics, Inc. (MPLT) filed a shelf registration statement that, once effective and with an accompanying prospectus supplement, would allow it to offer up to $400,000,000 in aggregate securities: voting common stock, preferred stock, debt securities and warrants. A separate $100,000,000 common-stock sales-agreement prospectus with Leerink Partners LLC is included within, not added to, the shelf amount. Any unsold portion may be offered under other shelf offerings after termination of the sales agreement.

MapLight intends to use net proceeds for general corporate purposes, including clinical trials, research and development, general and administrative expenses and capital expenditures. It may also use some proceeds for in-licensing, investment in or acquisition of complementary businesses, assets or technologies; it reports no current acquisition plans, commitments or agreements. MapLight said its Phase 2 ZEPHYR schizophrenia trial of ML-007C-MA had positive topline results in July 2026 and that it intends to discuss Phase 3 design with the FDA. It expects VISTA trial topline results in the second half of 2027. After June 2026 topline results from the Phase 2 IRIS trial of ML-004, it intends to discuss next development steps with the FDA for ASD irritability and then evaluate potential collaborations or funding alternatives.